A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects The objective of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe Rheumatoid Arthritis (RA) subjects.

• Country None
• organs None
• Specialty None

A study to provide access to continued treatment for subjects with prostate cancer who are currently participating in an enzalutamide clinical study The objective of the study is to provide access to continued treatment for subjects who are currently participating in an enzalutamide clinical study for their prostate cancer and who are continuing t...

• Country None
• organs None
• Specialty None

Study comparing Tivozanib in combination with mFOLFOX6 against Bevacizumab in combination with mFOLFOX6 in patients with bowel cancer To compare progression-free survival (PFS) between tivozanib in combination with mFOLFOX6 with bevacizumab in combination with mFOLFOX6 based on investigator radiological tumor assessment.

• Country None
• organs None
• Specialty None

A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate The objective of this study is to evaluate the safety and efficacy of ASP015K in moderate to severe Rheumatoid Arthritis (RA) subjects who are Methotrexate-Inadequate Responders (MTX-IR).

• Country None
• organs None
• Specialty None

A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 (ASP9785) vs. Bicalutamide in Castrate Men with Metastatic Prostate Cancer To determine the PFS of MDV3100 as compared to bicalutamide

• Country None
• organs None
• Specialty None

A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin’s Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant To determine objective response rate (ORR) (complete remission [CR] + partial remission [PR]) per [the International Working Group (IWG) Revised Response Criteria for Malignant Lymphomas (2007)].

• Country None
• organs None
• Specialty None

An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating Mutations (SOLAR Study) Estudio de Fase 3, abierto y aleatorizado, de la eficacia de ASP8273 frente a erlotinib o gefitinib como tratamiento de primera línea de pacientes con cáncer de pulmón no microcítico y mutaciones de activación del EGFR, en estadío IIIB/IV (Estudio SOLAR) To evaluate the progression free survival (PFS), based on independent radiologic review (IRR), of ASP8273 compared to erlotinib or gefitinib in patients with locally advanced, metastatic or unresectab...

• Country None
• organs None
• Specialty None

A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects with Moderate to Severe Psoriasis To establish the safety of alefacept when administered to adolescent subjects with moderate to severe psoriasis

• Country None
• organs None
• Specialty None

This multi center Phase III clinical trial will evaluate impact of maintenance therapy (maintain the response achieved during the first course of treatment) with the FLT3 (FMS-like tyrosine kinase 3) inhibitor gilteritinib on the RFS (Relapse free survival) of participants with FLT3/ITD AML (FMS-like tyrosine kinase 3 / Internal tandem duplication Acute myeloid leukemia) who have successfully undergone allogeneic transplant. Este ensayo clínico de Fase III, multicéntrico, va a evaluar el impacto del tratamiento de mantenimiento (para mantener la respuesta alcanzada durante el primer ciclo de tratamiento) con gilterinib, un inhibidor de la FLT3 (FMS-like tyrosine kinase 3), sobre la RFS (relapse free survival) de participantes con leucemia mieloide aguda con FLT3/ITD (FMS-like tyrosine kinase 3 / Internal tandem duplication) que han sido sometidos con éxito a un alotrasplante en este estudio The primary objective is to compare relapse-free survival (RFS) between participants with FLT3/ITD AML in CR1 who undergo HCT and are randomized to receive gilteritinib or placebo beginning after the ...

• Country None
• organs None
• Specialty None

Study to evaluate the efficacy and safety of combined use of tamsulosin and mirabegron in men who have enlarged prostate and an overactive bladder Eine doppelblinde, randomisierte, plazebokontrollierte multizentrische Phase IV-Studie zur Untersuchung der Wirksamkeit, Sicherheit und Verträglichkeit von Mirabegron bei männlichen Patienten mit überaktiver Blase (OAB), die wegen Symptomen des unteren Harntraktes (LUTS) im Zusammenhang mit einer benignen Prostatahyperplasie (BPH) mit dem Alpha-Blocker Tamsulosinhydrochlorid behandelt werden To study the efficacy of mirabegron versus placebo in men with OAB symptoms while taking tamsulosin hydrochloride for LUTS due to BPH.

• Country None
• organs None
• Specialty None